TY - JOUR
T1 - Clinical characteristics and outcomes of patients with stage I epithelial ovarian cancer compared with fallopian tube cancer
AU - Rauh-Hain, Jose Alejandro
AU - Foley, Olivia Wysong
AU - Winograd, Dina
AU - Andrade, Carolina
AU - Clark, Rachel Marie
AU - Vargas, Roberto Javier
AU - Hinchcliff, Emily Moss
AU - Esselen, Katherine Mc Kinley
AU - Horowitz, Neil Stuart
AU - Del Carmen, Marcela Guadalupe
N1 - Publisher Copyright:
© 2015 Elsevier Inc. All rights reserved.
PY - 2015/1/1
Y1 - 2015/1/1
N2 - Objective The purpose of this study was to compare clinical characteristics and survival between patients with stage I epithelial ovarian cancer and fallopian tube cancer. Study Design We identified women with stage I epithelial ovarian cancer and fallopian tube cancer who underwent treatment from 2000-2010. Correlation between categoric variables was assessed with χ2 test. The Kaplan-Meier survival analysis was used to generate overall survival data. Factors predictive of outcome were compared with the use of the log-rank test and Cox proportional hazards model. Results The study group consisted of 385 women with epithelial ovarian cancer and 43 women with fallopian tube cancer. Patients with fallopian tube cancer had a higher rate of stage IA disease (65% vs 48%; P =.02) and grade 3 tumors (60.4% vs 30.9%; P <.001). Patients with fallopian tube cancer had a significantly higher rate of breast cancer (25.6% vs 5.7%; P <.001) and BRCA 1 mutations (45.8% vs 9.1%; P <.001). There was no difference in the rates of platinum-based and paclitaxel chemotherapy between the groups. Women with fallopian tube cancer were more likely to have received ≥ 6 cycles of chemotherapy (58.1% vs 44.1%; P =.02). The 5-year disease-free survival rates were 100% in women with fallopian tube cancer and 93% in patients with epithelial ovarian cancer (P =.04). The 5-year overall survival rates were 100% and 95% for fallopian tube cancer and epithelial ovarian cancer, respectively (P =.7). Conclusion We found a higher rate of stage IA, grade 3, and serous carcinoma in fallopian tube cancer. Women with fallopian tube cancer had a higher rate of breast cancer. There was no difference in overall survival between the groups.
AB - Objective The purpose of this study was to compare clinical characteristics and survival between patients with stage I epithelial ovarian cancer and fallopian tube cancer. Study Design We identified women with stage I epithelial ovarian cancer and fallopian tube cancer who underwent treatment from 2000-2010. Correlation between categoric variables was assessed with χ2 test. The Kaplan-Meier survival analysis was used to generate overall survival data. Factors predictive of outcome were compared with the use of the log-rank test and Cox proportional hazards model. Results The study group consisted of 385 women with epithelial ovarian cancer and 43 women with fallopian tube cancer. Patients with fallopian tube cancer had a higher rate of stage IA disease (65% vs 48%; P =.02) and grade 3 tumors (60.4% vs 30.9%; P <.001). Patients with fallopian tube cancer had a significantly higher rate of breast cancer (25.6% vs 5.7%; P <.001) and BRCA 1 mutations (45.8% vs 9.1%; P <.001). There was no difference in the rates of platinum-based and paclitaxel chemotherapy between the groups. Women with fallopian tube cancer were more likely to have received ≥ 6 cycles of chemotherapy (58.1% vs 44.1%; P =.02). The 5-year disease-free survival rates were 100% in women with fallopian tube cancer and 93% in patients with epithelial ovarian cancer (P =.04). The 5-year overall survival rates were 100% and 95% for fallopian tube cancer and epithelial ovarian cancer, respectively (P =.7). Conclusion We found a higher rate of stage IA, grade 3, and serous carcinoma in fallopian tube cancer. Women with fallopian tube cancer had a higher rate of breast cancer. There was no difference in overall survival between the groups.
KW - BRCA breast
KW - cancer
KW - fallopian
KW - ovarian cancer
KW - tube cancer
UR - http://www.scopus.com/inward/record.url?scp=84928828568&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84928828568&partnerID=8YFLogxK
U2 - 10.1016/j.ajog.2014.12.013
DO - 10.1016/j.ajog.2014.12.013
M3 - Article
C2 - 25514761
AN - SCOPUS:84928828568
SN - 0002-9378
VL - 212
SP - 600.e1-600.e8
JO - American Journal of Obstetrics and Gynecology
JF - American Journal of Obstetrics and Gynecology
IS - 5
ER -